Major Depressive Disorder, Recurrent
9
1
1
6
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
22.2%
2 terminated out of 9 trials
75.0%
-11.5% vs benchmark
0%
0 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (9)
Peer-delivered and Technology-Assisted Integrated Illness Management and Recovery
Accelerated Intermittent Theta-Burst Stimulation Ameliorate Major Depressive Disorder by Regulating CAMKII Pathway
Cognitive Behavioural Therapy for the Treatment of Late Life Depression
MRS and Medication Response: A Pilot Study
Investigation of Brain Network Dynamics in Depression
Glutamate Probes in Adolescent Depression
Mechanisms of Mindfulness-Based Cognitive Therapy in the Treatment of Recurrent Major Depressive Disorder
Confirmation Bias Towards Treatments of Depressive Disorders in Social Tagging
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022)